Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients

Lieke H van der Helm, Ellen R M Scheepers, Nic J G M Veeger, Simon M G J Daenen, André B Mulder, Eva van den Berg, Edo Vellenga*, Gerwin Huls

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

47 Citations (Scopus)
438 Downloads (Pure)

Abstract

BACKGROUND: Treatment options in older acute myeloid leukaemia (AML) patients include intensive chemotherapy, best supportive care (BSC), and hypomethylating agents. Currently, limited data is available on hypomethylating agents in older AML patients in unselected patient populations.

METHODS: To compare the effectiveness of azacitidine with conventional therapy, we collected data of 227 consecutive AML patients (≥60 years) who were treated with azacitidine (N = 26), intensive chemotherapy (N = 90), or BSC (N = 97).

RESULTS: Azacitidine-treated patients were older and had more comorbidities, but lower white blood cell- and bone marrow blast counts compared with intensive chemotherapy patients. Complete or partial response was achieved in 42% of azacitidine-treated patients and in 73% of intensive chemotherapy patients (P = 0.005). However, the overall survival (OS) was similar (1-year-OS 57% versus 56%, P = 0.93; 2-year-OS 35% versus 35%, P = 0.92), and remained similar after correction for risk factors in a multivariate analysis. Patients treated with BSC had an inferior OS (1-year- and 2-year-OS 16% and 2%, P < 0.001). Compared to intensive chemotherapy, azacitidine-treated patients spent less days in the hospital (median in first three months 0.5 versus 56, P < 0.001), and needed less red blood cell and platelet transfusions (median per month 2.7 versus 7, P < 0.001 and 0.3 versus 5, P < 0.001) in the first three months.

CONCLUSIONS: Azacitidine treatment is associated with a comparable OS but higher tolerability in a subgroup of older AML patients compared with intensive chemotherapy. Patients receiving BSC had a poor prognosis.

Original languageEnglish
Article number29
Pages (from-to)29
Number of pages9
JournalJournal of Hematology & Oncology
Volume6
DOIs
Publication statusPublished - 16-Apr-2013

Keywords

  • Acute myeloid leukaemia
  • Older age
  • Azacitidine
  • Intensive chemotherapy
  • Best supportive care
  • ACUTE MYELOID-LEUKEMIA
  • CONVENTIONAL CARE REGIMENS
  • LOW-DOSE CYTARABINE
  • TRANSPLANTATION COMORBIDITY INDEX
  • RISK MYELODYSPLASTIC SYNDROMES
  • TRANS-RETINOIC ACID
  • EARLY DEATH
  • ELDERLY-PATIENTS
  • PHASE-III
  • INDUCTION THERAPY

Cite this